Jounce Therapeutics — Investor Presentation (August 2022)
34 slides from Jounce Therapeutics's investor presentation, Aug 30, 2022
Slide 1: Jounce Therapeutics Corporate Presentation
Jounce Therapeutics Corporate Presentation A NEXT GEN IMMUNOTHERAPY COMPANY AUGUST 2022 Exhib i t 99.1
Slide 2: Legal Disclaimer
Legal Disclaimer 2 Various statements concerning our future expectations, plans and prospects, including without limitation, our expectations regarding financial guidance, operating expenses and capital expenditures, the timing, initiation, progress, results of and release of data for clinical trial
Slide 3: The Jounce Difference
Proven Management Team • Founded by IO pioneers: Nobel Coley Lasker Prize • Cash runway into Q1 2024 The Jounce Difference 3 * Out licensed to Gilead Sciences, Inc. (clinical trial sponsor) The right immunotherapy for the right patients Productive Translational Science Platform • Various immune cell
Slide 4: The Challenge and Promise of IO Therapy
The Challenge and Promise of IO Therapy Lessons Learned Define New Opportunities 4 *PD-(L)1i = PD-1 inhibitor or PD-L1 inhibitor • Tumor with PD-(L)1i* approval • Minority of pts benefit • Tumor with PD-(L)1i approval • Majority pts do not respond • Tumor with no PD-(L)1i approval • Little to no ben
Slide 5: New Immune Cell Targets Are Needed For Next Gen IO
New Immune Cell Targets Are Needed For Next Gen IO Extend benefit to more patients and realize IO market potential 5 2022 IO Market $44B* 2026 IO market $74B & growing* Next Gen IO T cell-focused • Durable benefit in minority of patients • Many tumor types unresponsive • Majority of combos are chemo
Slide 6: The Core of Our Approach: Translational Science Platform
Human Tumor Samples The Core of Our Approach: Translational Science Platform 6 *PD= Pharmacodynamic Translational Drug Discovery • Sustainable engine • Multiple immune cell types • Goal of new IND every 12 – 18 months Reverse Translational Analysis • Patients with clinical outcomes • PD* and predict
Slide 7: Jounce Immunotherapy Pipeline
DISCOVERY PROGRAMS LILRB1 (ILT2) Myeloid & Lymphoid Bi-Specifics (Not Disclosed) Diverse Immune Cell Types Other Targets (Not Disclosed) PD-(L)1i Resistance Mechanisms Jounce Immunotherapy Pipeline 7 * Formerly JTX-1811 now out-licensed to Gilead Sciences, Inc. Program Target Biology Discovery Precl
Slide 8: Lead Macrophage Program: JTX-8064
Lead Macrophage Program: JTX-8064 8
Slide 9: JTX-8064: Potential Macrophage Checkpoint Inhibitor
JTX-8064: Potential Macrophage Checkpoint Inhibitor LILRB2 / ILT4 Target • LILRB2 is expressed on immunosuppressive macrophages • Immunosuppressive macrophages are a negative prognostic factor for many cancer types • Inhibition of LILRB2 reprograms macrophages to an immune active state and activates
Slide 10: LILRB2 (ILT4) May Inhibit Response to PD-(L)1i Therapy
LILRB2 (ILT4) May Inhibit Response to PD-(L)1i Therapy 10 • CD163 is a general marker for immunosuppressive macrophages • Similar associations between OS and CD163 have been reported for most tumor types in INNATE High LILRB2 / IFNγ Signature Ratio Correlates With Poor Response to PD- (L)1i Treatmen
Slide 11: JTX-8064 Inhibits A Unique Macrophage Checkpoint LILRB2 (ILT4)
JTX-8064 Inhibits A Unique Macrophage Checkpoint LILRB2 (ILT4) Proposed mechanism of action 11 Potential to Reverse PD-(L)1i Resistance JTX-8064 Immunosuppressive Macrophage (M2-like) Immune Activated Macrophage (M1-like) • Cytokine Production • Antigen Presentation • T-cell Activation
Slide 12: JTX-8064 Reprograms Macrophages to Enhance T Cell Responses
JTX-8064 Reprograms Macrophages to Enhance T Cell Responses 12 1. Cohen et al., Abstract 5007, AACR 2019; 2. McGrath et al., Abstract 1727, AACR 2021. JTX-8064 reprogrammed macrophages are more effective at stimulating T cells in co-culture2 Reprogramming of macrophages from M2 to an M1 state throug
Slide 13: Translational Informatics Defined Initial Tumor Types
Translational Informatics Defined Initial Tumor Types Higher Lower • Relative evaluation and ranking across all TCGA indications • Focus on 3 key RNA measures (LILRB2, Jounce TAM signature, IFNγ signature) • Figure sorted by LILRB2 13 TUMOR TYPE Testicular Cancer Mesothelioma Renal Cancer (clear cel
Slide 14: JTX-8064: INNATE Study Designed to Rapidly Demonstrate POC
Mono (n=22) & Combo (n=9) Dose Escalation Completed JTX-8064: INNATE Study Designed to Rapidly Demonstrate POC Preliminary Clinical Data by Year End 2022 • Full receptor occupancy at 300mg • 700mg RP2D* • No DLTs** (up to 1200mg) 14 Combo expansions • Ovarian (3/4L) • HNSCC (1L) • Sarcoma (2-4L) •
Slide 15: JTX-8064: INNATE Three Categories of Patients
JTX-8064: INNATE Three Categories of Patients Mechanistic potential to improve effectiveness of T cell-directed therapies 15 3/4L Ovarian Cancer (Mono & Combo) No Approved PD-(L)1i (IO Naïve Patients) 1L Head and Neck Squamous Cell Carcinoma Approved PD-1i (IO Naïve Patients) 2/3L clear cell Renal C
Slide 16: High Unmet Need in INNATE Indications
High Unmet Need in INNATE Indications * Clinical trial patients who received PD-(L)1i treatment beyond RECIST progression (PD-(L)1i as last prior therapy) References: 1 Gandara et al. Journal of Thoracic Oncology 2018; Kazandjian et al. Seminars in Oncology 2017; 2 Haddad et al. Cancer 2019; 3 Escud
Slide 17: JTX-8064: Anticipated INNATE Study Data in 2022
JTX-8064: Anticipated INNATE Study Data in 2022 Mono and Pimivalimab Combo Dose Escalation and Expansion 17 Preliminary Clinical Data by Year End At least 80 Phase 2 patients Complete mono and combo dose escalation data Preliminary mono and combo expansion cohort data Data from stage 1 of Si
Slide 18: Vopratelimab
Vopratelimab 18
Slide 19: Vopratelimab Biological Activity Distinct from CD8 Focused PD-(L)1i
Vopratelimab Biological Activity Distinct from CD8 Focused PD-(L)1i • Vopra is an IgG1 agonist antibody selective for ICOS (inducible co-stimulatory of T cells) • Activates CD4 T cells that have been primed by antigen presentation Clinical Learnings to Date • Well tolerated at all doses tested alone
Slide 20: SELECT: Randomized Phase 2 Predictive Biomarker Study
SELECT: Randomized Phase 2 Predictive Biomarker Study Clinical Study of Two Wholly Owned Antibodies with New Predictive Biomarker Phase 2 SELECT Randomized POC Study • Novel predictive biomarker approach – (TISvopra) RNA signature • IO naïve 2L NSCLC in 69 patients selected with TISvopra • Designed
Slide 21: SELECT Trial Top Line Results
SELECT Trial Top Line Results (ICR*; FAS) • Vopra continues to remain well tolerated and had no new safety signals • Expected differentiated pulsatile dosing was achieved 21 • Mean percent change from baseline in tumor size in all measurable lesions, averaged over 9 and 18 weeks • Continuous variabl
Slide 22: SELECT Trial Summary: RECIST Response & PFS
22 *ICR = Independent Central Review; **Disease Control Rate or DCR = CR + PR + SD of at least 9 weeks; Data cut date: 07 July 2022 JTX-4014 (pimi) (N=36) pimi + vopra 0.1 mg/kg (N=18) pimi + vopra 0.03 mg/kg (N=15) Overall response rate n (%) (95% CI) 9 (25.0) (12.12, 42.20) 3 (16.7) (3.58, 41.42)
Slide 23: SELECT Summary and Vopra Next Steps
SELECT Summary and Vopra Next Steps 23 • SELECT results do not support moving into registration studies as had been our previous goal and we expect to re-evaluate vopra in the context of our broader pipeline in the coming months • SELECT: Trends in improved mean tumor change over 9 and 18 weeks, ove
Slide 24: Pimivalimab PD-1 inhibitor
Pimivalimab PD-1 inhibitor 24
Slide 25: Pimivalimab (Pimi): PD-1 Inhibitor in POC Combo Studies
Pimivalimab (Pimi): PD-1 Inhibitor in 2 POC Combo Studies Well-Characterized PD-1 Antibody, Fully Human IgG4 Phase 2 SELECT Monotherapy Results • 9/36 (25.0%) overall response rate • Well tolerated Phase 1 Study Results* • 3/18 (16.7%) confirmed responses • No deaths or dose limiting toxicities Oppo
Slide 26: Discovery
Discovery 26
Slide 27: Jounce's Translational Science Platform
Jounce’s Translational Science Platform Deconstructing the Tumor Microenvironment to Identify Novel Therapeutics 27 T cell Identify targets uniquely tied to cell types of interest Profile human tumors for target expression on cell types of interest More IO Responsive Less IO Responsive Targets for l
Slide 28: JTX-1484 (Anti-LILRB4) Development Program
JTX-1484 (Anti-LILRB4) Development Program New addition to our differentiated cell type strategy 28 • Expressed on immuno-suppressive myeloid cells in the TME, including MDSCs, tolerogenic DCs and M2-like macrophages • Potent and specific blocker of human LILRB4 with favorable PK, pre-clinical safet
Slide 29: JTX-1484 (Anti-LILRB4): New Development Program
JTX-1484 (Anti-LILRB4): New Development Program Proposed mechanism of action 29
Slide 30: Milestones & Financials
Milestones & Financials 30
Slide 31: Upcoming Milestones
Vopratelimab (SELECT): Top-line results reported • Plan to submit full data clinical abstract to ESMO-IO in December 2022 • Safety and preliminary efficacy data • Performance of biomarker JTX-1484 (LILRB4): • Continue to advance towards a 2023 IND Discovery: • Continue to advance multiple new target
Slide 32: Financial Strength and Flexibility
Financial Strength and Flexibility NASDAQ: JNCE Strong Balance Sheet • Cash runway into Q1 2024 • Excludes any potential milestone payments • $162.3M in cash, cash equivalents and investments, as of June 30, 2022 Cash Guidance • 2022 gross cash burn $115M - $130M Common Stock Outstanding • 51.7M sha
Slide 33: The Jounce Difference
The Jounce Difference 33 Opportunity Compelling Pipeline Upcoming Catalysts Financial Strength Clinical data expected by year end from both lead programs Next generation IO with discovery across a variety of different immune cell types leading to an extensive pipeline Multiple large market opportuni
Slide 34: Jounce Therapeutics
Jounce Therapeutics JOUNCETX.COM 34
Jounce Therapeutics — Investor Presentation (August 2022) on 6ix